Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Vimta Labs Limited (VIMTALABS.NS)
Hyderabad, IN
Vimta Labs Limited provides specialized contract research and analytical testing services, operating both within India and internationally. Their extensive offerings encompass general laboratory analyses, comprehensive food and water quality testing, support for preclinical and clinical research, detailed structural and functional assessments of biological molecules, environmental impact studies, and clinical diagnostic reference laboratory capabilities. The company serves a wide array of industries, including pharmaceuticals, biopharmaceuticals, food production, consumer goods, electronics, electrical equipment, agrochemicals, healthcare, medical devices, and many more. Established in 1984, Vimta Labs Limited is headquartered in Hyderabad, India.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.29% | -2.91% | +5.85% | -0.18% | -24.04% | -19.01% | -0.16% | +153.69% | +285.17% | +1,179.02% | +439.63% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Medical - Diagnostics & Research: +7.9%+18.4% ★ Q1'26: +15.7% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%+15.2% Q1'26: +14.4% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+21.2% ★ Q1'26: +24.8% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+24.0% ★ Q1'26: +24.4% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%+18.5% ★ Q1'26: +19.7% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%+102.6% Q1'26: +105.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×0.02× ★ Q1'26: 0.02× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.07B
est: 1.30B (-17.6%)
|
1.25B
est: 1.42B (-12.1%)
|
1.54B
est: 1.45B (+6.0%)
|
1.83B
est: 1.30B (+41.0%)
|
2.13B
est: 1.42B (+49.9%)
|
1.81B
est: 1.45B (+24.5%)
|
2.09B
est: 1.75B (+19.0%)
|
2.76B
est: 2.25B (+22.9%)
|
3.15B
est: 2.63B (+19.9%)
|
3.18B
est: 2.78B (+14.3%)
|
3.44B
est: 3.76B (-8.4%)
|
3.99B
3.99B – 3.99B
+6.3% YoY
|
4.71B
4.71B – 4.71B
+18.0% YoY
|
| EBITDA |
181.56M
est: 391.40M (-53.6%)
|
194.53M
est: 426.63M (-54.4%)
|
278.02M
est: 436.55M (-36.3%)
|
458.00M
est: 391.40M (+17.0%)
|
581.04M
est: 426.63M (+36.2%)
|
316.53M
est: 436.55M (-27.5%)
|
533.46M
est: 527.18M (+1.2%)
|
802.74M
est: 675.32M (+18.9%)
|
966.38M
est: 351.46M (+175.0%)
|
902.01M
est: 1.28B (-29.7%)
|
1.26B
est: 1.20B (+5.3%)
|
1.27B
1.27B – 1.27B
+6.3% YoY
|
1.50B
1.50B – 1.50B
+18.0% YoY
|
| EBIT |
70.57M
est: 260.55M (-72.9%)
|
91.97M
est: 284.00M (-67.6%)
|
182.08M
est: 290.60M (-37.3%)
|
300.24M
est: 260.55M (+15.2%)
|
382.35M
est: 284.00M (+34.6%)
|
107.20M
est: 290.60M (-63.1%)
|
302.68M
est: 350.93M (-13.7%)
|
569.44M
est: 449.54M (+26.7%)
|
659.25M
est: 124.58M (+429.2%)
|
560.06M
est: 992.58M (-43.6%)
|
903.90M
est: 822.97M (+9.8%)
|
874.48M
874.48M – 874.48M
+6.3% YoY
|
1.03B
1.03B – 1.03B
+18.0% YoY
|
| Net Income |
50.62M
est: 140.11M (-63.9%)
|
64.34M
est: 156.79M (-59.0%)
|
105.92M
est: 107.20M (-1.2%)
|
164.33M
est: 140.11M (+17.3%)
|
253.11M
est: 78.40M (+222.9%)
|
68.45M
est: 53.60M (+27.7%)
|
214.05M
est: 67.39M (+217.6%)
|
413.30M
est: 133.66M (+209.2%)
|
481.72M
est: 94.57M (+409.4%)
|
410.09M
est: 583.27M (-29.7%)
|
673.42M
est: 615.14M (+9.5%)
|
775.12M
775.12M – 775.12M
+26.0% YoY
|
905.81M
905.81M – 905.81M
+16.9% YoY
|
| SGA |
49.08M
est: 186.54M (-73.7%)
|
59.40M
est: 203.33M (-70.8%)
|
59.74M
est: 208.06M (-71.3%)
|
65.57M
est: 186.54M (-64.8%)
|
85.75M
est: 203.33M (-57.8%)
|
96.23M
est: 208.06M (-53.7%)
|
664.92M
est: 251.25M (+164.6%)
|
89.00M
est: 321.85M (-72.3%)
|
115.21M
est: 1.34B (-91.4%)
|
109.82M
est: 401.00M (-72.6%)
|
1.01B
est: 428.91M (+136.2%)
|
455.75M
455.75M – 455.75M
+6.3% YoY
|
537.76M
537.76M – 537.76M
+18.0% YoY
|
| EPS |
2.00
est: 6.30 (-68.3%)
|
2.91
est: 7.05 (-58.7%)
|
4.79
est: 4.82 (-0.6%)
|
7.43
est: 6.30 (+17.9%)
|
11.45
est: 3.53 (+224.8%)
|
3.10
est: 2.41 (+28.6%)
|
4.84
est: 3.03 (+59.7%)
|
9.35
est: 6.01 (+55.6%)
|
10.89
est: 7.29 (+49.5%)
|
9.26
est: 26.10 (-64.5%)
|
15.14
est: 13.65 (+10.9%)
|
17.20
17.20 – 17.20
+26.0% YoY
|
20.10
20.10 – 20.10
+16.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | A | 4/5 | 4/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sivalinga Prasad Vasireddi | Executive Chairman | 23M | — |
| Satya Sreenivas Neerukonda | Executive Director | 17M | male |
| Harita Vasireddi | MD & Whole Time Director | 17M | female |
| Harriman Vungal D.Tech | Executive Director of Operations, Member of Scientific Advisory Board & Executive Director | 16M | male |
| Siva Rama Krishna Kambhampati | Chief Financial Officer | — | male |
| Sujani Vasireddi | Company Secretary & Compliance Officer | — | female |
| Upendra Bhatnagar | Senior Vice President of Preclinical | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VIMTALABS.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
